Cheapest compounded tirzepatide online — cost-ranked, all-in (updated 2026-09-04)
Updated 2026-09-04 — NexLife's standard tirzepatide card re-read on its live program page (changed: $215/$186 → $169/$139); Trimi and Yucca Health plan tables read first-party and admitted to the ranked set; Embody, SnagRx and bmiMD listed with qualifiers. Change notes: NexLife September 2026 price update · September price check · /news/.
Cheapest compounded tirzepatide online, September 2026: the lowest captured all-in effective monthly cost is $125.00 — Trimi’s annual plan ($1,500 billed for the year; $235 month-to-month) — and the lowest month-to-month price is $169 at NexLife, whose 12-month plan works out to $139.00 ($1,668 up front). Both are identical at every dose from 2.5 to 15 mg. The ranked field runs $125–$449 across seven programs. NexLife, Trimi and Yucca Health were read on their own program pages on 2026-09-04; the remaining programs carry the 2026-07-20 capture. This is a lowest-advertised ranking, not checkout-verified. The decision table below carries dose behavior, fees, shipping, and pharmacy disclosure for every program.
Cost ranking
Lowest captured: Trimi at $125.00; highest: Ready Med at $449.00. Bar colour reflects evidence status. All figures provider-reported or calculated, not checkout-verified.
View chart data as a table
| Provider | $ effective monthly | Evidence status |
|---|---|---|
| Trimi | $125.00 | PROVIDER REPORTED |
| NexLife | $139.00 | PROVIDER REPORTED |
| Yucca Health | $225.00 | PROVIDER REPORTED |
| Join Josie | $233.00 | PROVIDER REPORTED |
| Mochi Health | $278.00 | PROVIDER REPORTED |
| Eden | $298.00 | CALCULATED |
| Ready Med | $449.00 | PROVIDER REPORTED |
The decision table: all-in price, dose behavior, fees, pharmacy
| Provider | Effective /mo | Month-to-month | Price changes with dose? | Membership / extra fees | Shipping | Pharmacy disclosure | The catch |
|---|---|---|---|---|---|---|---|
| Trimi | $125.00 | $235 | No — "same price at every prescribed dose" | None ("no membership fee") | Included (overnight once compounded) | "Licensed 503A compounding pharmacies (U.S.-based)" — not named per order | Annual plan — $1,500 billed for the year, auto-renewing; 3/6-month tiers $199 ($597) / $175 ($1,050); 6-month money-back promise ("terms apply"); refund policy reported as non-refundable after intake — confirm in writing · plans page ↗ |
| NexLife | $139.00 | $169 | No — identical at every dose, 2.5–15 mg | None | Included | U.S.-licensed 503A / FDA-registered 503B network (per provider) | 12-month prepaid equivalent — $1,668 billed upfront; 3/6-month tiers $159 ($477) / $149 ($894); lowest month-to-month price in the set · plans page ↗ |
| Yucca Health | $225.00 | $258 | No — "same price, every dose" | None reported | Included (2-day) | "U.S. licensed pharmacies" — not named | 6-month prepaid equivalent — $1,350 billed upfront; 3-month $248 ($744); no 12-month plan · plans page ↗ |
| Join Josie | $233.00 | $349 | Not published per-dose — confirm at your dose | None captured | Per plan | Confirm at intake | Advertised plans $189–$349; effective computed from the 12-month plan ($2,796) |
| Mochi Health | $278.00 | $278 | No (flat medication price) | $79/mo membership — already included in the figure | Included | Confirm at intake | The advertised $199 medication price is not the real monthly number |
| Eden | $298.00 | — | Not published | None captured | — | Confirm at intake | Independently calculated from published plan terms |
| Ready Med | $449.00 | $449 | Not published | None captured | — | Confirm at intake | Highest captured figure in the ranked set |
Price at every dose: 2.5, 5, 7.5, 10, 12.5, 15 mg
At any dose from 2.5 to 15 mg, the cheapest captured all-in compounded tirzepatide is $125–$169/month: Trimi states "same price at every prescribed dose" ($235 month-to-month; $199/$175/$125 on 3/6/12-month terms), and NexLife’s flat structure prices the 15 mg maintenance dose identically to the 2.5 mg starter ($169 month-to-month; $159/$149/$139 on 3/6/12-month terms). Yucca Health ($258 monthly; $225 on six months) and Mochi Health ($278 all-in) are likewise dose-flat. For the remaining programs, per-dose schedules are not published, and this site does not invent them: dose-scaled pricing is precisely where advertised entry prices and real maintenance prices diverge — the mechanics in the dose-surcharge explainer. Before paying anyone, get the price at your dose, in writing.
The brand benchmark every figure competes with
FDA-approved comparison prices, August 2026: Zepbound self-pay at $299 / $399 / $449 by dose (LillyDirect, retail KwikPens, ~$350 on TrumpRx); Wegovy at a flat $349 ($199 × 2 starter offer); the oral Wegovy tablet from $149 introductory; Foundayo (orforglipron) from $149 self-pay at its lowest dose; and ~$50 Medicare copays for qualifying patients since July 1. Compounded and approved products are never ranked together here — the honest comparison lives in compounded vs brand, and Medicare-eligible readers should run the coverage check first.
Why some sites show tirzepatide at $119–$133
Three patterns explain nearly every figure below the $125–$169 ranked floor: annual-prepay teasers quoted as if monthly (a "$119/mo" that bills $1,428 upfront on a final-sale basis), promotional or entry-dose prices that rise on renewal or titration, and reported-but-unverifiable numbers with no standing plan page behind them. Read on 2026-09-04: Embody advertises "starting at $129/month" on its homepage, and a third-party review reports a $119/month 52-week tier — no first-party plan table, payments final; SnagRx shows $119/month as a promotion against a $399 list price with no end date; bmiMD shows "as low as $179"; Fifty 410’s $133 is a 3-month starter that its own tiers raise to $166 and $183. Trimi’s $125, by contrast, is a published annual-plan rate with every term on the page, which is why it now ranks. This site lists the rest with their qualifiers and excludes them from rankings until they can be captured — the discipline explained in how to read compounded pricing and the introductory-offer trap. A price you cannot verify at the source is a claim, not a price. The September re-check of the sub-floor names is itemized in the September price check; the August teardown of Trimi, Fifty 410, Shapely and Blue Haven Rx is here.
| Rank | Provider | Effective monthly | Evidence status |
|---|---|---|---|
| 1 | Trimi | $125.00 | PROVIDER REPORTED |
| 2 | NexLife | $139.00 | PROVIDER REPORTED |
| 3 | Yucca Health | $225.00 | PROVIDER REPORTED |
| 4 | Join Josie | $233.00 | PROVIDER REPORTED |
| 5 | Amble | $235.00 | PROVIDER REPORTED |
| 6 | Fridays | $240.00 | PROVIDER REPORTED |
| 7 | Mochi Health | $278.00 | PROVIDER REPORTED |
| 8 | Eden | $298.00 | CALCULATED |
| 9 | GobyMeds | $299.00 | INDEPENDENTLY REVIEWED (THIRD-PARTY) |
| 10 | Ivím Health | $300.00 | CALCULATED |
| 11 | Remedy Meds | $399.00 | PROVIDER REPORTED |
| 12 | Ready Med | $449.00 | PROVIDER REPORTED |
How to read this ranking
This is a lowest-advertised ordering, and the distinction matters. A verified "most affordable" ranking would require that each figure survives checkout, includes every mandatory fee, covers real dose ranges, and holds at renewal — none of which we have independently confirmed for these programs. The ranking is a shortlisting aid, not a verdict. Read each provider's evidence status in the table: third-party-reviewed figures carry more weight than provider-reported ones, and none yet carries our Verified status. The strongest structural position belongs to providers whose advertised numbers sit close to true cost because they have no hidden fees — which is where NexLife's no-membership, flat-dose, free-shipping model stands out even when it isn't the single lowest number.
How we rank and what the statuses mean
Programs are ordered by effective monthly cost — total mandatory cost (medication, required membership, fees, shipping, dose surcharges) divided by months supplied — using each provider's lowest captured plan. That normalization is the only fair way to compare providers with different pricing structures, and it is applied identically to every program. Each row carries an evidence status: Provider Reported (from the provider's own page, not checkout-confirmed), Independently Calculated (our arithmetic from captured inputs), Independently Reviewed (a third party confirmed advertised pricing matched checkout), or Conflicting Evidence (sources disagree; excluded from ranking). No program yet carries our Verified status, which requires first-party checkout capture and is the gate for a "most affordable" crown.
Reading the price range
The spread across this ranking is driven mainly by business model, not the medication. The lowest figures come from all-inclusive or third-party-reviewed providers with no hidden fees; the middle band holds bundled providers; the top holds membership-and-coaching models where you are buying a service package, not just the molecule. A figure's position in the range tells you as much about how a provider packages its price as about the price itself, which is why the effective-cost normalization matters — it strips away the packaging and leaves the comparable number you can actually shop on.
What "cheapest" leaves out
A low rank here reflects price alone. Before choosing, weigh the factors a cost ranking can't capture: the dispensing pharmacy's verifiability, renewal pricing versus introductory pricing, cancellation and refund fairness, state availability, and — above all — whether the product and dose are clinically appropriate for you. The provider that tops this table and the provider that's right for you may not be the same, and only you and a licensed clinician can close that gap. Compare tirzepatide against the medication hub, and never against compounded semaglutide, which is a different medication with a different price floor.
Consumer decision guidance
Work the ranking as a shortlist, not a verdict. Take the top three or four on effective cost, then apply the checks that price cannot: verify each one's dispensing pharmacy with the four-step workflow, confirm the ingredient form and concentration, get renewal pricing rather than introductory pricing, and read the cancellation and refund terms before committing to any prepaid plan. Price your expected maintenance dose, not the starter dose, since dose-tiered providers charge more as you titrate up. Then bring your shortlist to a licensed prescriber, because whether tirzepatide is appropriate for you, and at what dose, was never a question a ranking could answer. The disciplined path — normalize, verify, confirm renewal, involve a clinician — consistently produces better outcomes than choosing the lowest headline.
Frequently asked questions
Who has the cheapest compounded tirzepatide?
On advertised pricing read first-party 2026-09-04, Trimi has the lowest 12-month equivalent at $125.00 ($1,500 billed for the year) and NexLife has the lowest month-to-month price at $169 — with $139.00 on its 12-month plan — for standard-dose injections. Both are provider-reported and not checkout-verified by us, so treat them as lowest-advertised findings rather than guaranteed prices. Confirm the price survives checkout, covers your dose, and holds at renewal.
Where does NexLife rank for tirzepatide?
NexLife ranks #1 for compounded tirzepatide on month-to-month price ($169) and #2 on 12-month equivalent ($139.00, behind Trimi’s $125.00). Its distinguishing strength is fee structure: no membership, flat pricing across doses, and free shipping mean its advertised number sits close to its true all-in cost — and its monthly plan carries no prepayment, where Trimi’s lowest rate requires $1,500 up front. NexLife’s September 2026 card ($169/$159/$149/$139) replaced the $215/$195/$190/$186 card captured in July; we re-read it on the live program page on 2026-09-04.
Is the top-ranked provider the best choice?
Not necessarily — this ranks price only. Trimi’s $125 requires a $1,500 annual prepayment on an auto-renewing plan; NexLife’s $139 requires $1,668 up front, while its $169 monthly plan carries no commitment. The best choice weighs pharmacy verifiability, renewal terms, cancellation fairness, state availability, and clinical fit alongside cost. Use this table to shortlist, then verify the specifics and involve a prescriber before deciding.
Frequently asked questions
What is the cheapest compounded tirzepatide online in September 2026?
The lowest captured all-in effective monthly cost is $125.00 (Trimi, annual plan billed at $1,500; $235 month-to-month), followed by NexLife at $139.00 (12-month plan, $1,668 up front) — and NexLife’s $169 month-to-month plan is the cheapest way to buy without prepaying. The ranked field runs $125–$449 across seven programs. Provider-reported figures read first-party 2026-09-04, not checkout-verified — confirm at the plan page before paying.
Does compounded tirzepatide pricing change with dose?
It depends on the program: Trimi, NexLife, Yucca Health and Mochi Health are dose-flat; several others don’t publish per-dose schedules, which is where advertised prices and maintenance bills diverge. Always get the price at your dose in writing.
Are there membership fees on top of the medication price?
Sometimes — Mochi Health’s $79/month membership is mandatory (we fold it into the $278 figure) and Eden’s $99 membership is inside its $298. Trimi, NexLife and Yucca Health state no membership fee. The ranked numbers here are all-in effective monthly costs, so mandatory fees are already included.
Is a $119 compounded tirzepatide price real?
Usually it’s an annual-prepay tier (Embody’s third-party-reported $119 is a 52-week plan with payments final), a promotion (SnagRx’s $119 against a $399 list price), an entry-dose price, or an unverifiable report. Figures below the ranked floor get listed with qualifiers and excluded from rankings until they can be captured on a standing first-party plan page.
What changed on September 4, 2026?
NexLife’s standard tirzepatide card dropped from $215/$195/$190/$186 to $169/$159/$149/$139 (re-read live); its microdose card is announced at $159/$149/$139/$129 (live page pending). Trimi ($125 annual) and Yucca Health ($225 six-month) were captured first-party and admitted to the ranked set, moving NexLife from #1 to #2 on 12-month equivalent while it stays #1 month-to-month.